"
Team:Berkeley/HumanPractice/Economics
From 2013.igem.org
| Line 28: | Line 28: | ||
<div id="2"><div class = "heading-large"><a name="Assessing the Cost of Scale Up">Assessing the Cost of Scale Up</a></div> | <div id="2"><div class = "heading-large"><a name="Assessing the Cost of Scale Up">Assessing the Cost of Scale Up</a></div> | ||
<p> Even after our process is sufficiently optimized for scale up, several considerations must be taken into account to accurately assess economic feasibility. Here, we have included a list of considerations in developing a economically competitive dyeing methodology. The diagram, adapted from a presentation by Dr. Daniel Klein-Marcuschamer, combines the capital and operating costs associated with developing a bioreactor facility. Capital costs, such as the price of initially constructing a plant, equipment, intellectual property etc., amount to about half of the total costs associated with scale up. Operating costs such as the cost of maintaining the plant, feed chemicals (i.e. tryptophan and sugar), and consumables (i.e nickel resin and lysis beads) will also contribute to the over all affordability of our process. | <p> Even after our process is sufficiently optimized for scale up, several considerations must be taken into account to accurately assess economic feasibility. Here, we have included a list of considerations in developing a economically competitive dyeing methodology. The diagram, adapted from a presentation by Dr. Daniel Klein-Marcuschamer, combines the capital and operating costs associated with developing a bioreactor facility. Capital costs, such as the price of initially constructing a plant, equipment, intellectual property etc., amount to about half of the total costs associated with scale up. Operating costs such as the cost of maintaining the plant, feed chemicals (i.e. tryptophan and sugar), and consumables (i.e nickel resin and lysis beads) will also contribute to the over all affordability of our process. | ||
| - | < | + | <https://static.igem.org/mediawiki/2013/a/a8/Kleinlecture.png" width="600" /> |
Adapted from lecture by Dr. Daniel Klein-Marcuschamer; Director, Technoeconomic Analysis, JBEI; Manager, Technoeconomic Analysis, AIBN | Adapted from lecture by Dr. Daniel Klein-Marcuschamer; Director, Technoeconomic Analysis, JBEI; Manager, Technoeconomic Analysis, AIBN | ||
</p> | </p> | ||
Revision as of 00:46, 29 October 2013
From the data we gathered from ABPDU and our interview with an executive in the dyeing industry, we began to sketch out what our process may look like when scaled up.
Here, we put together a schematic of our envisioned scale up. Bacteria engineered to produce indican would be grown anaerobically, and the dyeing agent would be isolated from cell culture by lysing and centrifuging the mixture. Clothing could be dipped into indican and subsequently exposed to B-glucosidase, grown and purified in a second reactor.
There are several aspects of this method that remain open to question as we work to refine our laboratory scale dyeing process. Current experimentation with growing and secreting B-glucosidase in yeast could demonstrate that lysis and protein purification are unnecessary to our process. Indeed, we have already shown that impure B-glucosidase (i.e lysed E. coli cells that are producing the B-glucosidase) is capable of converting indican to indigo relatively quickly (data not shown). Experimenting with other similar glucosidases may also help us to choose the correct glucosidase given industrial conditions. Indican may also be secreted, as the glucose moiety on the molecule may allow us to engineer its transport out of the cell through a native glucose transporter
Even after our process is sufficiently optimized for scale up, several considerations must be taken into account to accurately assess economic feasibility. Here, we have included a list of considerations in developing a economically competitive dyeing methodology. The diagram, adapted from a presentation by Dr. Daniel Klein-Marcuschamer, combines the capital and operating costs associated with developing a bioreactor facility. Capital costs, such as the price of initially constructing a plant, equipment, intellectual property etc., amount to about half of the total costs associated with scale up. Operating costs such as the cost of maintaining the plant, feed chemicals (i.e. tryptophan and sugar), and consumables (i.e nickel resin and lysis beads) will also contribute to the over all affordability of our process.
